Your browser doesn't support javascript.
loading
A prospective study of BurstDR™ spinal cord stimulation for non-operated discogenic low back pain.
Mons, Martijn R; Chapman, Kenneth B; Terwiel, Chris; Joosten, Elbert A; Kallewaard, Jan-Willem.
Afiliação
  • Mons MR; Department of Anesthesiology and Pain Management, University Pain Clinic Maastricht (UPCM) Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
  • Chapman KB; Department of Translational Neuroscience, School for Mental Health and Neuroscience (MHeNS), University of Maastricht, Maastricht, The Netherlands.
  • Terwiel C; Department of Anesthesiology, New York University Langone Medical Center, New York City, New York, USA.
  • Joosten EA; Departement of Anesthesiology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Kallewaard JW; Department of Anesthesiology and Pain Management Arnhem, Rijnstate Hospital, Arnhem, The Netherlands.
Pain Pract ; 23(3): 234-241, 2023 03.
Article em En | MEDLINE | ID: mdl-36373868
ABSTRACT

INTRODUCTION:

Chronic discogenic low back pain (CD-LBP) is caused by degeneration of the disc due to trauma to the annulus or by unprovoked degeneration, resulting in chronic pain. Spinal cord stimulation (SCS) employing the BurstDR™ waveform has been shown to be an effective treatment in a variety of chronic pain conditions. The aim of this prospective case study was to determine the effect of BurstDR™ SCS on pain relief, disability, and patient satisfaction in a population with CD-LBP.

METHODS:

Seventeen subjects with CD-LBP received a SCS trial with BurstDR™ stimulation. Patients with >50% pain relief after a trial period of 2 weeks were permanently implanted (n = 15). Patients then rated LBP and leg pain using the numeric rating scale (NRS), Oswestry disability index (ODI), patient global impression of change (PGIC), EQ-5D quality of life, and painDETECT for neuropathic pain at baseline following trial, 3, 6, and 12 months after permanent implantation.

RESULTS:

Treatment with BurstDR™ SCS resulted in significant reduction of LBP as the NRS was reduced from 71.7 ± 7.3 at baseline to 42.5 ± 18.1 at 12 months. Average pain relief at 12 months was 42.5%. In patients with leg pain (n = 8), pain was significantly reduced from 66.9 ± 8.2 to 11.7 ± 10.4 at 12 months. PainDETECT scores for neuropathic pain significantly reduced from 18.9 ± 4.8 at baseline, and 14.8 ± 3.2 at 12 months. Baseline ODI score significantly reduced from 41.2 ± 12.8 to 25.8 ± 8.6 at 12 months. PGIC scores remained low from 2.6 ± 1.6 at 3 months, 2.5 ± 1.0 at 6 months, and 2.5 ± 1.3 at 12 months. EQ-5D-5L rates remained constant from baseline 56.10 ± 23.9 to 68.6 ± 12.9 at 12 months.

CONCLUSION:

BurstDR™ SCS resulted in significant reduction of back pain, leg pain, and quality of life in patients with CD-LBP and decreased the level of disability and generated positive patient satisfaction scores.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Lombar / Dor Crônica / Estimulação da Medula Espinal / Neuralgia Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Pain Pract Assunto da revista: NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Lombar / Dor Crônica / Estimulação da Medula Espinal / Neuralgia Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Pain Pract Assunto da revista: NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda